scholarly journals Genome-wide association study and the clinical application to chronic hepatitis C

Uirusu ◽  
2011 ◽  
Vol 61 (1) ◽  
pp. 15-24
Author(s):  
Masaya SUGIYAMA ◽  
Masashi MIZOKAMI
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Association Study ◽  
Chronic Hepatitis C ◽  
Clinical Application ◽  
Genome Wide Association Study ◽  
Genome Wide Association ◽  
Genome Wide

Genome-wide association study identifies a PSMD3 variant associated with neutropenia in interferon-based therapy for chronic hepatitis C

2014 ◽  
Vol 134 (3) ◽  
pp. 279-289 ◽  
Author(s):  
Etsuko Iio ◽  
Kentaro Matsuura ◽  
Nao Nishida ◽  
Shinya Maekawa ◽  
Nobuyuki Enomoto ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Association Study ◽  
Chronic Hepatitis C ◽  
Genome Wide Association Study ◽  
Genome Wide Association ◽  
Genome Wide

scholarly journals HLA-DQB1*03 Confers Susceptibility to Chronic Hepatitis C in Japanese: A Genome-Wide Association Study

PLoS ONE ◽  
2013 ◽  
Vol 8 (12) ◽  
pp. e84226 ◽  
Author(s):  
Daiki Miki ◽  
Hidenori Ochi ◽  
Atsushi Takahashi ◽  
C. Nelson Hayes ◽  
Yuji Urabe ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Association Study ◽  
Chronic Hepatitis C ◽  
Genome Wide Association Study ◽  
Genome Wide Association ◽  
Genome Wide ◽  
A Genome

scholarly journals Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients

2012 ◽  
Vol 56 (2) ◽  
pp. 313-319 ◽  
Author(s):  
Alexander J. Thompson ◽  
Paul J. Clark ◽  
Abanish Singh ◽  
Dongliang Ge ◽  
Jacques Fellay ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Association Study ◽  
Chronic Hepatitis C ◽  
Genome Wide Association Study ◽  
Genome Wide Association ◽  
Genome Wide ◽  
Chronic Hepatitis C Patients

scholarly journals Genome-Wide Association Study Identifies ZNF354C Variants Associated with Depression from Interferon-Based Therapy for Chronic Hepatitis C

PLoS ONE ◽  
2016 ◽  
Vol 11 (10) ◽  
pp. e0164418 ◽  
Author(s):  
Kayoko Matsunami ◽  
Nao Nishida ◽  
Naoko Kaneko ◽  
Kazuho Ikeo ◽  
Licht Toyo-oka ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Association Study ◽  
Chronic Hepatitis C ◽  
Genome Wide Association Study ◽  
Genome Wide Association ◽  
Genome Wide

Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study

2010 ◽  
Vol 138 (4) ◽  
pp. 1338-1345.e7 ◽  
Author(s):  
Andri Rauch ◽  
Zoltán Kutalik ◽  
Patrick Descombes ◽  
Tao Cai ◽  
Julia Di Iulio ◽  
...  
Keyword(s):  
Genetic Variation ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Treatment Failure ◽  
Association Study ◽  
Chronic Hepatitis C ◽  
Genome Wide Association Study ◽  
Genome Wide Association ◽  
Genome Wide ◽  
A Genome

scholarly journals Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study

2019 ◽  
Vol 69 (11) ◽  
pp. 1969-1979
Author(s):  
Willem P Brouwer ◽  
Henry L Y Chan ◽  
Pietro Lampertico ◽  
Jinlin Hou ◽  
Pisit Tangkijvanich ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Association Study ◽  
Chronic Hepatitis B ◽  
Genetic Variants ◽  
Genome Wide Association Study ◽  
Pegylated Interferon ◽  
Hbv Dna ◽  
Genome Wide Association ◽  
Genome Wide

AbstractBackground(Pegylated) Interferon ([Peg]IFN) therapy leads to response in a minority of chronic hepatitis B (CHB) patients. Host genetic determinants of response are therefore in demand.MethodsIn this genome-wide association study (GWAS), CHB patients, treated with (Peg)IFN for at least 12 weeks ± nucleos(t)ide analogues within randomized trials or as standard of care, were recruited at 21 centers from Europe, Asia, and North America. Response at 24 weeks after (Peg)IFN treatment was defined as combined hepatitis B e antigen (HBeAg) loss with hepatitis B virus (HBV) DNA <2000 IU/mL, or an HBV DNA <2000 IU/mL for HBeAg-negative patients.ResultsOf 1144 patients, 1058 (92%) patients were included in the GWAS analysis. In total, 282 (31%) patients achieved the response and 4% hepatitis B surface antigen (HBsAg) loss. GWAS analysis stratified by HBeAg status, adjusted for age, sex, and the 4 ancestry components identified PRELID2 rs371991 (B= −0.74, standard error [SE] = 0.16, P = 3.44 ×10–6) for HBeAg-positive patients. Importantly, PRELID2 was cross-validated for long-term response in HBeAg-negative patients. G3BP2 rs3821977 (B = 1.13, SE = 0.24, P = 2.46 × 10–6) was associated with response in HBeAg-negative patients. G3BP2 has a role in the interferon pathway and was further examined in peripheral blood mononuclear cells of healthy controls stimulated with IFNα and TLR8. After stimulation, less production of IP-10 and interleukin (IL)-10 proteins and more production of IL-8 were observed with the G3BP2 G-allele.ConclusionsAlthough no genome-wide significant hits were found, the current GWAS identified genetic variants associated with (Peg)IFN response in CHB. The current findings could pave the way for gene polymorphism-guided clinical counseling, both in the setting of (Peg)IFN and the natural history, and possibly for new immune-modulating therapies.Clinical Trials RegistationNCT01401400.

Sign in / Sign up

Export Citation Format

Share Document